A recent meta-analysis of 20 randomized clinical trials of tamoxifen efficacy (n approximately 20 K) demonstrated that both ER+/PR+ and ER+/PR- patients show significant benefit from tamoxifen therapy, and PR is not a useful marker for predicting tamoxifen response in ER+ breast cancer [14]. This evidence concerns the gene ESR1 and breast cancer.